PMC:7105881 / 26183-26415 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T114","span":{"begin":19,"end":26},"obj":"Body_part"}],"attributes":[{"id":"A114","pred":"fma_id","subj":"T114","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1).\nTABLE 1 Subunit Vaccines against SARS-CoVa.\nName Antigenicity and functionality Adjuvant Route Animal models Antib"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T114","span":{"begin":146,"end":150},"obj":"Disease"}],"attributes":[{"id":"A114","pred":"mondo_id","subj":"T114","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1).\nTABLE 1 Subunit Vaccines against SARS-CoVa.\nName Antigenicity and functionality Adjuvant Route Animal models Antib"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T274","span":{"begin":212,"end":218},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_33208"}],"text":"of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1).\nTABLE 1 Subunit Vaccines against SARS-CoVa.\nName Antigenicity and functionality Adjuvant Route Animal models Antib"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T120","span":{"begin":19,"end":26},"obj":"Chemical"}],"attributes":[{"id":"A120","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1).\nTABLE 1 Subunit Vaccines against SARS-CoVa.\nName Antigenicity and functionality Adjuvant Route Animal models Antib"}

{"project":"LitCovid-sentences","denotations":[{"id":"T157","span":{"begin":112,"end":156},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1).\nTABLE 1 Subunit Vaccines against SARS-CoVa.\nName Antigenicity and functionality Adjuvant Route Animal models Antib"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T508","span":{"begin":17,"end":26},"obj":"PG_1"},{"id":"T509","span":{"begin":38,"end":47},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T510","span":{"begin":146,"end":150},"obj":"SP_10"},{"id":"T98807","span":{"begin":17,"end":26},"obj":"PG_1"},{"id":"T16034","span":{"begin":38,"end":47},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T88526","span":{"begin":146,"end":150},"obj":"SP_10"}],"text":"of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1).\nTABLE 1 Subunit Vaccines against SARS-CoVa.\nName Antigenicity and functionality Adjuvant Route Animal models Antib"}